In an upcoming phase 2b filing-enabling study, adult patients with AML will receive mocravimod as an adjunctive and maintenance therapy while undergoing HSCT. The study will assess improvements in ...

CMV reactivation is a significant post-transplant complication, affecting 60-70% of seropositive HSCT recipients ... has completed Phase 1 and Phase 2 studies, demonstrating tolerability and ...

Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.